ATTORNEY GENERAL WRIGLEY URGES CONSUMERS TO CLAIM COMPENSATION FOR INFLATED GENERIC DRUG PRICES

September 23, 2026

_{Media Contact: Suzie Weigel 701.328.2210}

BISMARCK, ND – BISMARCK, ND – Attorney General Drew H. Wrigley is urging consumers to check their eligibility for compensation for certain generic drug purchases and to submit a claim for compensation here.

Wrigley announces that the claims process is now open for eligible consumers to recover money from settlements with multiple generic drug manufacturers over allegations of unlawful inflation of generic drug prices. This month, the U.S. District Court for the District of Connecticut granted preliminary approval of a plan, filed by Wrigley and a coalition of 47 other attorneys general, to distribute settlement funds paid by generic drug manufacturers in exchange for settlement of claims that those companies illegally conspired to raise the prices of generic drugs.

The coalition previously announced settlements with Glenmark, Lannett, Bausch, Apotex, Heritage, and Heritage’s parent company, Emcure, totaling approximately $96.5 million. The distribution plan aims to return millions of dollars from those settlement funds to consumers potentially harmed by elevated prices for the generic drugs that are the subject of a series of antitrust cases the coalition has been litigating since 2016.

“We are committed to returning money to North Dakotans who paid more than they should have for these drugs,” said Wrigley. “I encourage everyone to review the criteria, determine whether you qualify, and, if you do, submit a claim,” adds Wrigley.

If you purchased a generic drug listed here between May 2009 and December 2019, you may be eligible for compensation. To determine your eligibility or learn more about how to submit a claim, you should call 1-866-290-0182 (Toll-Free), email info@AGGenericDrugs.com, or visit the settlement website www.AGGenericDrugs.com.

Wrigley is part of a coalition of nearly all states and territories engaged in a series of antitrust cases. The first complaint, filed in 2016, included Heritage and 17 other corporate defendants, two individual defendants, and 15 generic drugs. The second complaint was filed in 2019 against Teva Pharmaceuticals and 21 of the nation’s largest generic drug manufacturers. The complaint names 16 individual senior executive defendants. The third complaint, to be tried first, focuses on 80 topical generic drugs that account for billions of dollars of sales in the United States and names 26 corporate defendants and 10 individual defendants. The coalition filed a fourth complaint earlier this year, alleging that Novartis AG, Sandoz Group AG and Sandoz AG, are liable for Sandoz’s alleged conduct and for fraudulently transferring assets. Seven pharmaceutical executives have been cooperating to support the coalition’s claims in these cases.

The above-mentioned cases stem from a series of investigations built on evidence from several cooperating witnesses at the core of the different conspiracies, millions of documents, and a massive phone record database. Each complaint addresses a different set of drugs and defendants and lays out an interconnected web of competing industry executives who regularly met and communicated with each other, providing ample opportunity to form illegal agreements. The complaints note that defendants used terms like “fair share,” “playing nice in the sandbox,” and “responsible competitor” to unlawfully discourage competition, raise prices, and enforce an ingrained culture of collusion.

Alaska, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Northern Mariana Islands, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, U.S. Virgin Islands, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming have joined.

###

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.